This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Self-scoring

Log in to view the self-scoring content

For optimal functionality, please access the image bank and self-scoring pages via desktop devices. Some functionality may be lost on mobile devices.

loading gif

Your request is being processed.
It might take some seconds to load the images and texts.
Please, kindly wait...

Images were obtained from multiple sources. Some images were obtained as courtesy from © Agilent Technologies, Inc. Reproduced with permission, courtesy of Agilent Technologies, Inc. Additional images were provided by other sources with respective approval for use.

No personalised or identifiable information is collected during this scoring exercise. Anonymised information may be utilised for MSD internal use.

Supporting documentation

KEYTRUDA® (pembrolizumab)
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-PDO-01097 | Date of Preparation: September 2020

Self-scoring

To help in practicing TPS and CPS scoring of PD-L1 in different indications, this section allows you to review images of PD-L1 stained slides (with corresponding H&E (haematoxylin and eosin) slides) and check your knowledge and PD-L1 expression estimate against the consensus score for each case.

loading gif

Your request is being processed.
It might take some seconds to load the images and texts.
Please, kindly wait...

Images were obtained from multiple sources. Some images were obtained as courtesy from © Agilent Technologies, Inc. Reproduced with permission, courtesy of Agilent Technologies, Inc. Additional images were provided by other sources with respective approval for use.

No personalised or identifiable information is collected during this scoring exercise. Anonymised information may be utilised for MSD internal use.

HNSCC = Head and Neck Squamous Cell Carcinoma

Supporting documentation

KEYTRUDA® (pembrolizumab)
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-PDO-01097 | Date of Preparation: September 2020